• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于人群的大阪癌症登记处的宫颈癌流行病学和临床分析。

Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry.

机构信息

Department of Obstetrics and Gynecology, Osaka University Graduate School of Medicine, Suita, Osaka, Japan.

Department of Gynecology, Tama-Hokubu Medical Center, Tokyo Metropolitan Health and Medical Treatment Corporation, Higashimurayama, Tokyo, Japan.

出版信息

Cancer Res. 2019 Mar 15;79(6):1252-1259. doi: 10.1158/0008-5472.CAN-18-3109. Epub 2019 Jan 11.

DOI:10.1158/0008-5472.CAN-18-3109
PMID:30635276
Abstract

Cervical cancer screening rate is extremely low and the governmental recommendation of HPV vaccine has been suspended for 5 years in Japan. Here, we utilized data from the Osaka Cancer Registry, collected between 1976 and 2012, to evaluate cervical cancer trends in Japan. Age-adjusted incidence, relative survival, and conditional survival rates were calculated using multiple imputation methods and period analyses in 25,826 cervical cancer cases. Association of survival rates and clinical factors, including patients' age, clinical stage, and treatment procedures, were also analyzed. A trend for significantly decreasing age-adjusted incidence of cervical cancer (per 100,000) began in 1976 but reversed after 2000, increasing significantly to date (annual percent change = 3.8, 95% confidence interval, 2.7-4.8; age-adjusted rate: 28.0 in 1976, 9.1 in 2000, 14.1 in 2012). The 10-year relative survival rate improved significantly after 2002, especially in cases of "localized" and "adjacent organs" disease; this was likely due to the introduction of concurrent chemotherapy and radiation. The conditional 5-year relative survival rate improved significantly yearly until the fourth survival year. In the surgery-based group, we observed no age-dependent differences in outcomes. Unexpectedly, however, prognosis for younger age groups was poorer in the radiation-based treatment group. These results indicate that although relative survival rates have recently increased, treatment for more advanced cases with distant metastasis requires further improvement. In addition, this study is the first to suggest that age might be an important predictor of radiotherapy resistance in cervical cancer. A large-cohort analysis of cervical cancer cases reveals that age-adjusted incidence in Japan has increased since 2000 and that age may negatively correlate with resistance to radiotherapy.

摘要

日本的宫颈癌筛查率极低,HPV 疫苗的政府推荐已暂停 5 年。在这里,我们利用了 1976 年至 2012 年间收集的大阪癌症登记处的数据,评估了日本宫颈癌的趋势。使用多项缺失方法和时期分析,计算了 25826 例宫颈癌病例的年龄调整发病率、相对生存率和条件生存率。还分析了生存率与临床因素(包括患者年龄、临床分期和治疗程序)的关联。宫颈癌年龄调整发病率(每 10 万人)呈显著下降趋势(1976 年开始,但 2000 年后逆转,至今呈显著上升趋势,年变化百分比=3.8,95%置信区间,2.7-4.8;年龄调整率:1976 年 28.0,2000 年 9.1,2012 年 14.1)。2002 年后,10 年相对生存率显著提高,特别是在“局部”和“相邻器官”疾病患者中;这可能是由于同步放化疗的引入。条件 5 年相对生存率逐年显著提高,直到第四年生存。在手术组中,我们没有观察到与年龄相关的结果差异。然而,出乎意料的是,在基于放疗的治疗组中,年龄较小的患者预后较差。这些结果表明,尽管相对生存率最近有所提高,但对有远处转移的更晚期病例的治疗需要进一步改善。此外,这项研究首次表明,年龄可能是宫颈癌放疗抵抗的一个重要预测因素。对大量宫颈癌病例的分析表明,自 2000 年以来,日本的年龄调整发病率有所增加,并且年龄可能与对放疗的抵抗力呈负相关。

相似文献

1
Epidemiologic and Clinical Analysis of Cervical Cancer Using Data from the Population-Based Osaka Cancer Registry.基于人群的大阪癌症登记处的宫颈癌流行病学和临床分析。
Cancer Res. 2019 Mar 15;79(6):1252-1259. doi: 10.1158/0008-5472.CAN-18-3109. Epub 2019 Jan 11.
2
The incidence, treatment and prognosis of cervical carcinoma in young women: a retrospective analysis of 4,975 cases in Japan.年轻女性宫颈癌的发病率、治疗及预后:日本4975例病例的回顾性分析
Eur J Gynaecol Oncol. 2010;31(1):37-43.
3
Cervical adenocarcinoma and squamous cell carcinoma incidence trends among Tunisian women.突尼斯女性宫颈癌和鳞状细胞癌的发病率趋势
Asian Pac J Cancer Prev. 2010;11(3):777-80.
4
Incidence, mortality and survival from invasive cervical cancer in Vaud, Switzerland, 1974-1991.1974 - 1991年瑞士沃州浸润性宫颈癌的发病率、死亡率和生存率
Ann Oncol. 1994 Oct;5(8):747-52. doi: 10.1093/oxfordjournals.annonc.a058980.
5
Cervical cancer incidence and survival in Korea: 1993-2002.韩国1993 - 2002年宫颈癌的发病率及生存率
Int J Gynecol Cancer. 2006 Sep-Oct;16(5):1833-8. doi: 10.1111/j.1525-1438.2006.00708.x.
6
The rising incidence of adenocarcinoma relative to squamous cell carcinoma of the uterine cervix in the United States--a 24-year population-based study.美国子宫颈腺癌发病率相对于鳞状细胞癌呈上升趋势——一项基于人群的24年研究。
Gynecol Oncol. 2000 Aug;78(2):97-105. doi: 10.1006/gyno.2000.5826.
7
Five-year overall survival and prognostic factors in patients with cervical cancer in Bulgaria.保加利亚宫颈癌患者的五年总生存率及预后因素
J BUON. 2008 Jul-Sep;13(3):363-8.
8
Temporal trends in the epidemiology of cervical cancer in South Africa (1994-2012).南非宫颈癌的流行病学的时间趋势(1994-2012)。
Int J Cancer. 2018 Nov 1;143(9):2238-2249. doi: 10.1002/ijc.31610. Epub 2018 Aug 7.
9
Italian cancer figures--Report 2015: The burden of rare cancers in Italy.意大利癌症数据——2015年报告:意大利罕见癌症的负担
Epidemiol Prev. 2016 Jan-Feb;40(1 Suppl 2):1-120. doi: 10.19191/EP16.1S2.P001.035.
10
Cancer of the uterine cervix in Norway by histologic type, 1970-84.1970 - 1984年挪威子宫颈癌的组织学类型
J Natl Cancer Inst. 1987 Aug;79(2):199-205.

引用本文的文献

1
Gynecologic Cancer Screening and Prevention: State of the Science and Practice.妇科癌症筛查与预防:科学现状与实践
Curr Treat Options Oncol. 2025 Mar;26(3):167-178. doi: 10.1007/s11864-025-01301-z. Epub 2025 Feb 27.
2
A questionnaire survey of cervical and breast cancer screening among female employees and employees' spouses.一项针对女性员工及其配偶的宫颈癌和乳腺癌筛查问卷调查。
Sci Rep. 2025 Feb 12;15(1):5277. doi: 10.1038/s41598-025-86863-6.
3
Systematic literature review on the clinical and economic burden of human papillomavirus-related diseases in select areas in the Asia-Pacific region.
系统文献回顾:亚太地区选定地区人乳头瘤病毒相关疾病的临床和经济负担。
Hum Vaccin Immunother. 2024 Dec 31;20(1):2425535. doi: 10.1080/21645515.2024.2425535. Epub 2024 Nov 18.
4
Human papillomavirus vaccine to prevent CIN3 or worse (CIN3+): A nationwide case-control study in Japan.预防CIN3或更严重病变(CIN3+)的人乳头瘤病毒疫苗:日本一项全国性病例对照研究
Cancer Sci. 2025 Jan;116(1):226-232. doi: 10.1111/cas.16375. Epub 2024 Oct 25.
5
Cemiplimab monotherapy in Japanese patients with recurrent or metastatic cervical cancer.西妥昔单抗单药治疗复发性或转移性宫颈癌的日本患者。
Cancer Med. 2024 Sep;13(18):e70236. doi: 10.1002/cam4.70236.
6
Human Papillomavirus Vaccination by Birth Fiscal Year in Japan.日本按财政年度统计的人乳头瘤病毒疫苗接种情况。
JAMA Netw Open. 2024 Jul 1;7(7):e2422513. doi: 10.1001/jamanetworkopen.2024.22513.
7
P16/Ki67 Dual Staining in Glandular Cell Abnormalities of the Uterine Cervix.P16/Ki67双重染色在子宫颈腺细胞异常中的应用
Cancers (Basel). 2024 Apr 23;16(9):1621. doi: 10.3390/cancers16091621.
8
Even though active recommendation for HPV vaccination has restarted, Japan's rates have not recovered.尽管已经重新开始积极推荐 HPV 疫苗接种,但日本的接种率仍未恢复。
Cancer Sci. 2024 Jul;115(7):2410-2416. doi: 10.1111/cas.16167. Epub 2024 May 2.
9
Effectiveness of catch-up and routine program of the 9-valent vaccine on cervical cancer risk reduction in Japan.九价疫苗补种和常规接种程序对降低日本宫颈癌发病风险的效果。
Cancer Sci. 2024 Mar;115(3):916-925. doi: 10.1111/cas.16055. Epub 2023 Dec 30.
10
Twenty-five-year mortality trends of four major histological subtypes of cervical cancer: a population-based study using the Osaka cancer registry data.宫颈癌四种主要组织学亚型的25年死亡率趋势:一项基于大阪癌症登记数据的人群研究
Front Oncol. 2023 Nov 27;13:1233354. doi: 10.3389/fonc.2023.1233354. eCollection 2023.